Nonresponse to anti-TNFα therapy in patients with CD is associated with higher blood TREM1 levels (Verstockt et al., 2019a), whereas low blood TREM1 levels predict better anti-TNFα response in patients with IBD (Verstockt et al., 2019b). This evidence concerns the gene TREM1 and inflammatory bowel disease.